Double-target treatment for breast cancer
Breast cancer is one of the most common malignant tumours in women. Double-target treatment is an innovative treatment strategy for breast cancer. The two-target treatment consists mainly of two target-oriented drugs, usually one-on-one and one-on-one-on-one. The monotole resistance is a single clone antibodies of human origin, which can be specifically combined with the extra-cell structure of human skin growth factor receptor 2 (HER-2). Her – 2 has been expressed in about 20% – 30% of cases of breast cancer, which is closely related to the invasive growth of tumours, increased risk of relapse. The monotron resistance to tumour cell proliferation is inhibited by blocking the transmission of intracellular growth signals by combining it with Her-2. Pattojole is also a single cloned antibody, unlike the point at which tutocholes act, and the combination of the two can more fully block the HeR-2 signal route. The single-combination of Patoporium to different areas of Her – 2 proteins, in synergy with the one-size-fits-all capricorn, interferes in many ways with the growth of tumour cells and further inhibits their survival and breeding. The two-target treatment applies mainly to breast cancer patients of Her – 2 positives. Her – 2-positive breast cancer tends to have a high risk of relapse and aggression. In early HeR – 2 positive breast cancer patients, new assisted double-target treatment (pre-operative use of double-target drugs) can increase the rate of total pathological decomposition, i.e. cancer cells are almost non-existent in tumour tissues subject to surgical removal. This is important for improving the long-term survival of patients. In the case of late-stage Her – 2 positive breast cancer, double-target treatment can prolong the patient ‘ s non-progressive and total survival and improve the quality of life of the patient. 1. In terms of new assistive treatments – Several clinical trials show that there is a significant improvement in the pathology of two-target treatments for early HeR – 2-positive breast cancers compared to single-target treatments (only one-size-fits-all). For example, in the NeoSphere study, the pathology of the two-target treatment group reached 45.8 per cent, while the single-target treatment group was only 29 per cent. – This higher rate of complete pathology mitigation may translate into better long-term projections. The risk of re-emergence is reduced and the duration of life is expected to increase. 2. In the area of assistive treatment (post-operative treatment), studies have found that dual-target treatment can further reduce the risk of recurrence of HeR – 2 positive breast cancer. The APHINITY study shows that in the population as a whole, double-target treatment reduces the risk of re-emergence by 19 per cent compared to the single anti-synthesis treatment. The benefits of dual-target treatment are more evident for patients with high risk factors (e.g. lymphoma positive). 3. In the case of advanced treatment – later Her – 2-positive breast cancer patients are more complex and have poorer prognosis. Double-target treatment shows the advantage of longer life periods among these patients. CLEOPATRA studies show that a combination of two-target treatments compared to a single anti-cosmotherapy treatment can increase the median non-progressive life of patients from 12.4 to 18.5 months and the median total life from 40.8 to 56.5 months. 1. Cardinal toxicity – monopolization of tutophorus and single resistance of Pattophorus may have some effect on the heart. The risk of cardiac toxicity increased when the two were used together. This is mainly reflected in incomplete left-heart functions and heart failure. However, through rigorous heart function monitoring, such as regular cardiac ultrasounds, and the assessment of indicators such as left cardiocardial blood fractions, cardiac abnormalities can be detected in a timely manner and interventions can be made. 2. Injection response – Some patients may react with a fluid during drug infusion, such as fever, cold warfare, rashes, breathing difficulties, etc. Most of these reactions occur during the first infusion, and can be effectively mitigated by such measures as slowing down the rate of the infusion and giving anti-allergy drugs. Diarrhoea – The adverse effects of diarrhoea in the anti-use process may occur, although in most cases the extent of diarrhoea is relatively low and can be addressed by, for example, adjusting diets and giving laxatives. Dual-target treatment provides more effective treatment options for Her-2-positive breast cancer patients, but in the course of treatment there is a need to pay close attention to adverse reactions and to weigh the benefits and risks of treatment in order to achieve optimal treatment outcomes.
